Embecta Corp. (EMBC)
Healthcare · NMS
Fundamentals
Valuation and ratings
Embecta Corp. trades at USD3.29, which is 130% below the USD7.57 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 37 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 1.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
EMBC dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | USD0.160 | 2 |
| 2025 | USD0.600 | 4 |
| 2024 | USD0.600 | 4 |
| 2023 | USD0.600 | 4 |
| 2022 | USD0.300 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
EMBC earnings and analyst estimates
Recommendation mix, 4 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Embecta Corp.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
EMBC passes 5 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
11 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Yacktman Asset Management, YACKTMAN ASSET MANAGEMENT LP$32.46M · 0.4% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$14.09M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$4.71M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$3.72M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$3.46M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Embecta Corp. (EMBC) undervalued?
Against our discounted cash flow estimate of USD7.57, EMBC at USD3.29 is 130% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own EMBC?
11 of the institutions we track reported a position in EMBC in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is EMBC's P/E ratio?
EMBC trades at 1.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Embecta Corp. (EMBC) pay a dividend?
Yes. Embecta Corp. yields 14.15% at the current share price. It has paid USD0.460 per share over the trailing twelve months. It has paid a dividend in each of the last 4 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
When does EMBC report earnings next?
Embecta Corp. is scheduled to report on 6 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for EMBC, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.